1. Introduction {#sec1-jcm-07-00553}
===============

The health-related quality of life (H-QOL) is a patient-centered clinical outcome that is used internationally for patients with various diseases, including diabetes mellitus, and cardiovascular diseases, renal diseases and malignancies \[[@B1-jcm-07-00553],[@B2-jcm-07-00553],[@B3-jcm-07-00553],[@B4-jcm-07-00553]\]. Chronic liver diseases (CLDs) can also affect H-QOL \[[@B5-jcm-07-00553],[@B6-jcm-07-00553],[@B7-jcm-07-00553],[@B8-jcm-07-00553],[@B9-jcm-07-00553]\]. Due to the adverse clinical and patient-reported outcomes, and the economic burden of CLDs, improving H-QOL in patients with CLDs should be a major treatment goal \[[@B5-jcm-07-00553],[@B6-jcm-07-00553],[@B7-jcm-07-00553],[@B8-jcm-07-00553],[@B9-jcm-07-00553]\]. A previous study reported that higher H-QOL was associated with favorable clinical outcome in patients with CLDs and increasing the number of pivotal clinical trials have adopted H-QOL as additional study endpoints \[[@B10-jcm-07-00553],[@B11-jcm-07-00553]\]. The most extensively used assessment methods for H-QOL is the 36-Item Short Form Health Survey (SF-36) \[[@B12-jcm-07-00553],[@B13-jcm-07-00553],[@B14-jcm-07-00553],[@B15-jcm-07-00553],[@B16-jcm-07-00553]\].

Skeletal muscle mass (SMM) increases till 20 years, peaks between 20 and 50 years, and decreases by approximately 1% after the age of 50 years, due to changes in muscle fiber type and size \[[@B17-jcm-07-00553]\]. Sarcopenia is a clinical disease entity that is defined by diminished muscle function and SMM \[[@B18-jcm-07-00553],[@B19-jcm-07-00553],[@B20-jcm-07-00553],[@B21-jcm-07-00553],[@B22-jcm-07-00553],[@B23-jcm-07-00553],[@B24-jcm-07-00553],[@B25-jcm-07-00553],[@B26-jcm-07-00553],[@B27-jcm-07-00553],[@B28-jcm-07-00553]\]. It can be associated with worse clinical outcomes and higher health care costs in various diseases, and there is therefore urgent need for the establishment of methods for improving sarcopenia \[[@B18-jcm-07-00553],[@B19-jcm-07-00553],[@B20-jcm-07-00553],[@B21-jcm-07-00553],[@B22-jcm-07-00553],[@B23-jcm-07-00553],[@B24-jcm-07-00553],[@B25-jcm-07-00553],[@B26-jcm-07-00553],[@B27-jcm-07-00553],[@B28-jcm-07-00553]\]. This also applies to CLD patients \[[@B19-jcm-07-00553],[@B21-jcm-07-00553],[@B23-jcm-07-00553]\]. Sarcopenia is the main component of malnutrition, and it is primarily responsible for the unfavorable clinical consequences that are observed in CLD patients \[[@B19-jcm-07-00553],[@B21-jcm-07-00553],[@B23-jcm-07-00553]\]. Liver cirrhosis (LC) can easily complicate sarcopenia, due to impaired protein synthesis \[[@B19-jcm-07-00553]\]. Currently, the Japanese Society of Hepatology (JSH) reported that the original criteria for sarcopenia in liver diseases, with reference to the Asian criteria for sarcopenia \[[@B18-jcm-07-00553],[@B22-jcm-07-00553]\]. The JSH criteria use hand grip strength (HGS) for muscle strength assessment, and bioimpedance analysis (BIA) and/or computed tomography for muscle mass assessment, while unlike the Asian criteria for sarcopenia, there is no age restriction for the assessment of sarcopenia in the JSH criteria, because younger patients with severe advanced CLDs such as liver failure are likely to be involved in sarcopenia \[[@B18-jcm-07-00553]\].

However, as far as we are aware, scarce data regarding the relevance between H-QOL and HGS and SMM in CLD patients are currently available, although there are several reports where it is not diminished SMM, but diminished muscle strength, that is related to the weakness of physical function in patients with diabetes-related dementia, and that HGS is an important correlate of health in breast cancer survivors \[[@B29-jcm-07-00553],[@B30-jcm-07-00553]\]. We hypothesized that HGS rather than SMM may affect H-QOL in CLD patients. To clarify these clinical research questions, we primarily sought to examine the influence of HGS and SMM on H-QOL, as evaluated by the SF-36 questionnaire, as compared with other clinical data (liver functional data, nutritional data, etc.) in patients with CLDs.

2. Patients and Methods {#sec2-jcm-07-00553}
=======================

2.1. Patients {#sec2dot1-jcm-07-00553}
-------------

A total of 410 CLD patients with data for HGS and SMM, using BIA and the SF-36 scores available were admitted to our hospital between November 2013 and August 2018. Each attending physician asked study subjects to receive body composition analysis, and to complete SF-36 questionnaires. Of these, 15 patients with hepatic encephalopathy, advanced malignancies, severe inflammatory diseases, or severe psychiatric diseases that potentially affect H-QOL were excluded. Six subjects with severe ascites were also excluded from the study subjects, because BIA can be challenging in patients with severe fluid retention, that is, overestimates could occur in the calculation of skeletal muscle mass index (SMI) by using BIA in such patients \[[@B19-jcm-07-00553]\]. Three hundred and eighty-nine patients were therefore analyzed. LC was determined using histological and/or imaging studies. FIB-4 index as determined by age, aspartate aminotransferase, alanine aminotransferase, and platelet count, and the controlling nutritional (CONUT) score as determined by serum albumin value, total cholesterol value, and lymphocyte count, were calculated as described elsewhere \[[@B31-jcm-07-00553],[@B32-jcm-07-00553]\].

2.2. Questionnaire {#sec2dot2-jcm-07-00553}
------------------

Study subjects were asked to complete the Japanese version of the SF-36 (self-reported questionnaire). It consists of 36 items and is classified into multi-item (eight items) scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health perception (GH), vitality (VT), social functioning (SF), role emotion (RE), and mental health (MH) \[[@B33-jcm-07-00553]\]. The physical component summary score (PCS) and the mental component summary score (MCS) were additionally included in this questionnaire, and its validity was well confirmed \[[@B33-jcm-07-00553]\]. Thus, a total of 10 items were evaluated.

2.3. Measurement of HGS and SMI {#sec2dot3-jcm-07-00553}
-------------------------------

The measurement of HGS was based on the current guidelines \[[@B18-jcm-07-00553]\]. Two measurements of HGS were performed on both the left and right sides. The better measurement on each side was used, and HGS was calculated as the mean of these values. SMI was defined as "appendicular SMM/(height (m))^2^" using BIA. Based on the current guidelines, patients with decreased HGS (d-HGS) were defined as those with HGS \< 26 kg for men and \<18 kg for women. Similarly, patients with decreased SMM (d-SMM) were defined as those with SMI \< 7.0 kg/m^2^ for men and \<5.7 kg/m^2^ for women \[[@B18-jcm-07-00553]\]. As described earlier, the JSH criteria for sarcopenia in liver disease determines sarcopenia based on muscle strength and muscle mass regardless of age, because younger patients with advanced LC status may be involved in sarcopenia \[[@B18-jcm-07-00553]\].

First, the impacts of HGS and SMM on the SF-36 scores across 10 items were examined for all cases and several subgroups according to the LC status, gender, and age. Subsequently, the relationships between the SF-36 scores across 10 items and baseline data were investigated. Factors associated with the SF-36 scores were also studied by using multivariate analysis. We received the ethical approval from the ethics committee of our hospital (approval no, 2296). The protocol in the study strictly observed all regulations of the Declaration of Helsinki.

2.4. Statistical Considerations {#sec2dot4-jcm-07-00553}
-------------------------------

As for continuous parameters, Student's *t* test, Mann--Whitney *U* test or the Pearson correlation coefficient *r* were employed to assess between-group differences, as applicable. In categorical parameters, Fisher's exact tests or the Pearson *χ*^2^ test was employed to assess between-group differences, as applicable. Factors with *p* \< 0.1 for the correlation with the SF-36 scores across 10 items were subjected to multivariate regression analysis with multiple predictive variables by using the least squares method, to identify candidate parameters. Unless otherwise mentioned, data are indicated as number or average ± standard deviation (SD). All items of SF-36 were analyzed separately, and we considered variables of *p* \< 0.05 as being statistically significant variables. The JMP 13.2 (SAS Institute Inc., Cary, NC, USA) was employed to carry out the statistical analysis.

3. Results {#sec3-jcm-07-00553}
==========

3.1. Patient Baseline Data {#sec3dot1-jcm-07-00553}
--------------------------

Baseline data in this study (*n* = 389, 198 men and 191 women, average age = 62.0 years) are indicated in [Table 1](#jcm-07-00553-t001){ref-type="table"}. LC was found in 148 patients (38.0%). The average ± SD HGS and SMI in male patients were 33.6 ± 8.7 kg and 7.5 ± 1.1 kg/m^2^, respectively, and those in female patients were 20.9 ± 5.2 kg and 6.0 ± 0.7 kg/m^2^, respectively. Sarcopenia, as defined by the JSH criteria, was observed in 27 male patients (13.6%) and 34 female patients (17.8%) \[[@B18-jcm-07-00553]\]. In LC patients, sarcopenia was identified in 39 patients (26.4%), while in non-LC patients, it was identified in 22 patients (9.1%).

Between-group differences (the d-HGS group (*n* = 93) vs. the non-decreased HGS (nd-HGS) group (*n* = 296)) were noted with statistical significance in age, gender, presence of LC, serum albumin, platelet count, lymphocyte count, total cholesterol, CONUT score, FIB-4 index, and SMI (both male and female). While in the d-SMM group (*n* = 159) vs. the non-decreased SMI (nd-SMM) group (*n* = 230), between-group differences in age, gender, body mass index (BMI), FIB-4 index, serum creatinine, and HGS (both male and female) reached significance. The corresponding average ± SD values and *p* values are listed in [Table 1](#jcm-07-00553-t001){ref-type="table"}.

Between-group differences (LC patients (*n* = 148) vs. non-LC patients (*n* = 151)) were noted with statistical significance in the items of PF, RP, GH, VT, SF, RE, and PCS, suggesting that LC patients had poorer H-QOL compared with non-LC patients. Corresponding average ± SD values, 95% confidence intervals (CIs) and *P* values were summarized in [Table 2](#jcm-07-00553-t002){ref-type="table"}.

3.2. Impact of HGS and SMM on the SF-36 Scores for all Cases {#sec3dot2-jcm-07-00553}
------------------------------------------------------------

The average ± SD SF-36 scores (95% CIs) in the d-HGS and nd-HGS groups (*n* = 93 and 296), and the d-SMM and nd-SMM groups (*n* = 159 and 230) for all cases are presented in [Table 3](#jcm-07-00553-t003){ref-type="table"}. Between-group differences (the d-HGS group vs. the nd-HGS group) in the items of PF (*p* \< 0.0001), RP (*p* \< 0.0001), BP (*p* = 0.0043), VT (*p* = 0.0011), SF (*p* \< 0.0001), RE (*p* \< 0.0001), and PCS (*p* \< 0.0001) reached significance, while SF-36 scores in the d-SMI group were significantly higher than those in the nd-SMI group in the items of PF (*p* = 0.0032), SF (*p* = 0.0031) and RE (*p* = 0.0030). ([Figure 1](#jcm-07-00553-f001){ref-type="fig"}a,b).

3.3. Subgroup Analysis 1: Impact of HGS and SMM on the SF-36 Scores for LC Patients {#sec3dot3-jcm-07-00553}
-----------------------------------------------------------------------------------

The average ± SD SF-36 scores \[95% CIs\] in the d-HGS and nd-HGS groups (*n* = 61 and 87), and the d-SMM and nd-SMM groups (*n* = 66 and 82) for LC patients are shown in [Table 3](#jcm-07-00553-t003){ref-type="table"}. Between-group differences (the d-HGS group vs. the nd-HGS group) in the items of PF (*p* = 0.0002), RP (*p* = 0.0006), BP (*p* = 0.0002), VT (*p* = 0.0132), SF (*p* = 0.0112), RE (*p* \< 0.0001), and PCS (*p* \< 0.0001) reached significance, while in the d-SMM group vs. the nd-SMI group, the differences were noted with significance in the items of PF (*p* = 0.0252) and RE (*p* = 0.0131) ([Figure 2](#jcm-07-00553-f002){ref-type="fig"}a,b).

3.4. Subgroup Analysis 2: Impact of HGS and SMM on the SF-36 Scores for Non-LC Patients {#sec3dot4-jcm-07-00553}
---------------------------------------------------------------------------------------

The average ± SD SF-36 scores (95% CIs) in the d-HGS and nd-HGS groups (*n* = 32 and 209) and the d-SMM and nd-SMM groups (*n* = 94 and 147) for non-LC patients are demonstrated in [Table 3](#jcm-07-00553-t003){ref-type="table"}. Between-group differences (the d-HGS group vs. the nd-HGS group) in the items of PF (*p* = 0.0002), RP (*p* = 0.0006), RE (*p* = 0.0002), and PCS (*p* = 0.0018) reached significance, while in the d-SMM group vs. the nd-SMM group, no significant difference was noted in all items ([Figure 3](#jcm-07-00553-f003){ref-type="fig"}a,b).

3.5. Subgroup Analysis 3: Impact of HGS and SMM on the SF-36 Scores for Male Patients {#sec3dot5-jcm-07-00553}
-------------------------------------------------------------------------------------

The average ± SD SF-36 scores (95% CIs) in the d-HGS and nd-HGS groups (*n* = 36 and 162) and the d-SMM and nd-SMM groups (*n* = 92 and 106) for male patients are indicated in [Table 3](#jcm-07-00553-t003){ref-type="table"}. Between-group differences (the d-HGS group vs. the nd-HGS group) in the items of PF (*p* \< 0.0001), RP (*p* \< 0.0001), SF (*p* \< 0.0001), RE (*p* \< 0.0001) and PCS (*p* \< 0.0001) reached significance, while the SF-36 scores in the d-SMM group were significantly higher than those in the nd-SMM group in the items of PF (*p* = 0.0451) and RP (*p* = 0.0035) ([Figure 4](#jcm-07-00553-f004){ref-type="fig"}a,b).

3.6. Subgroup Analysis 4: Impact of HGS and SMM on the SF-36 Scores for Female Patients {#sec3dot6-jcm-07-00553}
---------------------------------------------------------------------------------------

The average ± SD SF-36 scores \[95% CIs\] in the d-HGS and nd-HGS groups (*n* = 57 and 134) and the d-SMM and nd-SMM groups (*n* = 66 and 125) for female patients are indicated in [Table 3](#jcm-07-00553-t003){ref-type="table"}. Between-group differences (the d-HGS group vs. the nd-HGS group) in the items of PF (*p* \< 0.0001), RP (*p* \< 0.0001), BP (*p* = 0.0432), VT (*p* = 0.0006), SF (*p* = 0.0012), RE (*p* \< 0.0001), PCS (*p* \< 0.0001) and MCS (*p* = 0.0326) reached significance, while in the d-SMM group vs. the nd-SMI group, the difference was observed with significance only in the item of PF (*p* = 0.0124). ([Figure 5](#jcm-07-00553-f005){ref-type="fig"}a,b).

3.7. Subgroup Analysis 5: Impact of HGS and SMM on the SF-36 Scores for Patients Aged ≥65 Years {#sec3dot7-jcm-07-00553}
-----------------------------------------------------------------------------------------------

The average ± SD SF-36 scores (95% CIs) in the d-HGS and nd-HGS groups (*n* = 74 and 121) and the d-SMM and nd-SMM groups (*n* = 110 and 85) for patients aged ≥65 years are indicated in [Table 3](#jcm-07-00553-t003){ref-type="table"}. Between-group differences (the d-HGS group vs. the nd-HGS group) in the items of PF (*p* = 0.0001), RP (*p* \< 0.0001), BP (*p* = 0.0111), VT (*p* = 0.0021), SF (*p* \< 0.0001), RE (*p* \< 0.0001), and PCS (*p* \< 0.0001) reached significance, while in the d-SMM group vs. the nd-SMM group, no significant differences were observed in all items ([Figure 6](#jcm-07-00553-f006){ref-type="fig"}a,b).

3.8. Subgroup Analysis 6: Impact of HGS and SMM on the SF-36 Scores for Patients Aged \<65 Years {#sec3dot8-jcm-07-00553}
------------------------------------------------------------------------------------------------

The average ± SD SF-36 scores (95% CIs) in the d-HGS and nd-HGS groups (*n* = 19 and 175) and the d-SMM and nd-SMM groups (*n* = 49 and 145) in patients aged \<65 years are indicated in [Table 3](#jcm-07-00553-t003){ref-type="table"}. Between-group differences (the d-HGS group vs. the nd-HGS group) in the items of PF (*p* \< 0.0001), GH (*p* = 0.0088), RE (*p* = 0.0281), and PCS (*p* = 0.0081) reached significance, while in the d-SMM group vs. the nd-SMM group, between-group difference was significant only in the item of SF (*p* = 0.0286) ([Figure 7](#jcm-07-00553-f007){ref-type="fig"}a,b).

3.9. Relationship between the SF-36 Scores and Baseline Parameters in Male Patients and Female Patients {#sec3dot9-jcm-07-00553}
-------------------------------------------------------------------------------------------------------

Correlation coefficients and *p* values between the SF-36 scores across 10 items, and baseline parameters in male patients and female patients are summarized in [Table 4](#jcm-07-00553-t004){ref-type="table"}.

In male patients, HGS significantly correlated with PF (*r* = 0.32, *p* \< 0.0001), RP (*r* = 0.25, *p* = 0.0007), RE (*r* = 0.16, *p* = 0.0324), and PCS (*r* = 0.29, *p* \< 0.0001), while SMI did not significantly correlate with any item. Serum albumin level significantly correlated with all items other than MH and HCS.

In female patients, HGS significantly correlated with PF (*r* = 0.35, *p* \< 0.0001), RP (*r* = 0.18, *p* = 0.0195), VT (*r* = 0.23, *p* = 0.0022), SF (*r* = 0.18, *p* = 0.0179), RE (*r* = 0.19, *p* = 0.0112), MH (*r* = 0.17, *p* = 0.0222), PCS (*r* = 0.28, *p* = 0.0003), and MCS (*r* = 0.15, *p* = 0.0446), whereas SMI significantly correlated with PF only (*r* = 0.20, *p* = 0.0053). Serum albumin levels significantly correlated with all items other than MH.

3.10. Multivariate Analyses of Factors Linked to the SF-36 Scores in Male Patients and Female Patients {#sec3dot10-jcm-07-00553}
------------------------------------------------------------------------------------------------------

In male patients, multivariate analyses of factors for the SF-36 scores revealed that HGS was significantly linked to PF (*p* = 0.0031), RP (*p* = 0.0185) and PCS (*p* = 0.0421), while serum albumin was a significant factor for PF (*p* = 0.0048), RP (*p* = 0.0004), VT (*p* = 0.0327), SF (*p* = 0.0085), RE (*p* = 0.0002) and PCS (*p* \< 0.0001) ([Table 5](#jcm-07-00553-t005){ref-type="table"}).

In female patients, multivariate analyses of factors for the SF-36 scores revealed that HGS was significantly linked to PF (*p* = 0.0034), VT (*p* = 0.0150), RE (*p* = 0.0422), and PCS (*p* = 0.0191), whereas serum albumin did not significantly correlate with any item ([Table 5](#jcm-07-00553-t005){ref-type="table"}).

4. Discussion {#sec4-jcm-07-00553}
=============

The loss of SMM in CLDs is caused by the progressive withdrawal of anabolism, and an increase in catabolism \[[@B34-jcm-07-00553]\]. The liver is an essential organ that is involved in protein, fat, and carbohydrate metabolism, and energy generation \[[@B35-jcm-07-00553],[@B36-jcm-07-00553]\]. H-QOL in CLDs has been demonstrated to be significantly compromised, and the decrease in H-QOL in CLDs is frequently overlooked or unrecognized \[[@B37-jcm-07-00553]\]. To our knowledge, this is the first study demonstrating the relevance between HGS and SMM and H-QOL in CLD patients. To elucidate these issues is clinically of importance, because sarcopenia in liver diseases has been gaining much attention these days, due to its high prognostic predictability, and its definition includes HGS and SMM \[[@B18-jcm-07-00553],[@B19-jcm-07-00553],[@B20-jcm-07-00553],[@B21-jcm-07-00553],[@B22-jcm-07-00553],[@B23-jcm-07-00553],[@B24-jcm-07-00553],[@B25-jcm-07-00553],[@B26-jcm-07-00553],[@B27-jcm-07-00553],[@B28-jcm-07-00553]\]. We therefore conducted the current analysis.

In our results, mean values in the d-HGS and nd-HGS groups were largely different, with statistical significance in the items of PF and PCS for all cases and all subgroup analyses, while in comparison, between the d-SMM and nd-SMM groups, such tendencies were not observed. Additionally, our multivariate analyses revealed that HGS was an independent predictor associated with PF and PCS irrespective of gender; however, in terms of mentality-related domains such as MH or MCS, both HGS and SMI appeared not to have an impact on the SF-36 scores. These results demonstrated that not SMM, but HGS has a strong influence on the physiological domains in the SF-36, which may be linked to clinical outcomes in CLD patients \[[@B11-jcm-07-00553]\]. Numerous previous studies have reported that SMM is an independent outcome predictor in CLD patients \[[@B18-jcm-07-00553],[@B19-jcm-07-00553],[@B21-jcm-07-00553],[@B23-jcm-07-00553],[@B25-jcm-07-00553],[@B26-jcm-07-00553]\]. However, reviewing our current results, decreased SMM itself is not possibly a prognostic factor, but the presence of a large number of patients with diminished muscle strength in diminished SMM patients leads to poor prognosis. Our data showing that SMI was significantly correlated with HGS, both in males (*r* = 0.37, *p* \< 0.0001) and females (*r* = 0.46, *p* \< 0.0001), support this hypothesis. In this respect, the current results seem to shed some insights on the better understanding of muscle mass and muscle weakness in CLD patients.

Notably, as presented in [Table 1](#jcm-07-00553-t001){ref-type="table"}, age affected both HGS and SMI, while the presence of LC, serum albumin, and the CONUT score affected only HGS, and BMI affected only SMM. As described above, SMM decreases by approximately 1% after the age of 50 years, owing to changes in muscle fiber type and size \[[@B17-jcm-07-00553]\]. These morphological and functional changes of skeletal muscle due to aging appear to account for the impact of aging on HGS and SMM. On the other hand, our current results denoted that d-SMM does not occur by poor nutritional state alone, and d-HGS does not occur by lower BMI alone, although the mechanisms for these remains unclear. In our comparison of the SF-36 scores across 10 items in patients with and without LC, significant differences were noted in numerous items, which are in agreement with previous reports \[[@B19-jcm-07-00553],[@B21-jcm-07-00553],[@B38-jcm-07-00553],[@B39-jcm-07-00553]\]. LC patients tend to have worse H-QOL and exercise training can be a pivotal recommendation for LC patients \[[@B38-jcm-07-00553]\]. While there have been few reports regarding H-QOL in non-LC patients. In that sense, our data are worthy of report.

In our multivariate analyses, serum albumin was an independent factor in several items of the SF-36 in male patients, while in female patients, serum albumin was not significant in any item of the SF-36. The average ± SD serum albumin levels in male and female in this study were 4.1 ± 0.53 g/dL and 4.2 ± 0.47 g/dL (*p* = 0.4726). Gender differences of hormones, including estrogen and progesterone or physiological and psychological attributes of men and women, may be attributed to our current results, however, it is likely that the ability of protein synthesis is associated with H-QOL in male CLD patients \[[@B40-jcm-07-00553],[@B41-jcm-07-00553]\]. In our previous investigation, we have reported that serum levels of myostatin, which is a negative regulator of muscle protein synthesis, significantly differed in male and female LC patients \[[@B23-jcm-07-00553]\].

The proportions of sarcopenia in LC and non-LC patients were 26.4% and 9.1%, respectively, in this study. Sarcopenia includes primary and secondary sarcopenia \[[@B18-jcm-07-00553]\]. LC patients may have secondary sarcopenia due to impaired protein synthesis, and non-LC patients may have aging-related primary sarcopenia \[[@B18-jcm-07-00553]\]. Clinicians should fully consider the etiology for sarcopenia in each patient.

Several limitations related to the study warrant mention. Firstly, the study was a single-center observational study with a retrospective nature. Secondly, the study data was derived from a Japanese liver disease population data, and additional investigations on other races are required to further verify and extend the application to other races. Thirdly, HGS can vary depending on patients' daily life activities. Fourthly, patients with massive ascites or hepatic encephalopathy, who are potentially involved in sarcopenia were excluded, due to the lack of reliability in the BIA or the self-reported questionnaire, creating bias. Finally, the interpretation of our results should be done cautiously, since the direction of the association between the SF-36 scores and HGS or SMM remains unclear, due to the cross-sectional nature of our data. Nevertheless, our study results denoted that patients with d-HGS scored lower in the SF-36 vs. those with nd-HGS, especially in the physical health domains. In conclusion, HGS appears to have a strong impact on H-QOL in patients with CLDs, and exercise may be beneficial for improving H-QOL. In CLD patients with d-HGS, clinicians should be aware of the presence of CLD patients with decreased H-QOL.

5. Conclusions {#sec5-jcm-07-00553}
==============

HGS appears to have a strong impact on H-QOL in patients with CLDs.
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![The SF-36 scores across 10 items in the decreased and non-decreased HGS groups (**a**), and the decreased and non-decreased SMM groups (**b**) for all cases (*n* = 389). The average scores in each item of the SF-36 were plotted.](jcm-07-00553-g001){#jcm-07-00553-f001}

![The SF-36 scores across 10 items in the decreased and non-decreased HGS groups (**a**), and the decreased and non-decreased SMM groups (**b**) in LC patients (*n* = 148). The average scores in each item of the SF-36 were plotted.](jcm-07-00553-g002){#jcm-07-00553-f002}

![The SF-36 scores across 10 items in the decreased and non-decreased HGS groups (**a**), and the decreased and non-decreased SMM groups (**b**) in non-LC patients (*n* = 241). The average scores in each item of the SF-36 were plotted.](jcm-07-00553-g003){#jcm-07-00553-f003}

![The SF-36 scores across 10 items in the decreased and non-decreased HGS groups (**a**), and the decreased and non-decreased SMM groups (**b**) in male patients (*n* = 198). The average scores in each item of the SF-36 were plotted.](jcm-07-00553-g004){#jcm-07-00553-f004}

![The SF-36 scores across 10 items in the decreased and non-decreased HGS groups (**a**), and the decreased and non-decreased SMM groups (**b**) in female patients (*n* = 191). The average scores in each item of the SF-36 were plotted.](jcm-07-00553-g005){#jcm-07-00553-f005}

![The SF-36 scores across 10 items in the decreased and non-decreased HGS groups (**a**), and the decreased and non-decreased SMM groups (**b**) in patients aged \>65 years (*n* = 195). The average scores in each item of the SF-36 were plotted.](jcm-07-00553-g006){#jcm-07-00553-f006}

![The SF-36 scores across 10 items in the decreased and non-decreased HGS groups (**a**), and the decreased and non-decreased SMM groups (**b**) in patients aged \<65 years (*n* = 194). The average scores in each item of the SF-36 were plotted.](jcm-07-00553-g007){#jcm-07-00553-f007}

jcm-07-00553-t001_Table 1

###### 

Baseline characteristics.

  Variables                             All Cases (*n* = 389)   Decreased HGS (*n* = 93)   Non-Decreased HGS (*n* = 296)   *p* Value   Decreased SMM (*n* = 159)   Non-decreased SMM (*n* = 230)   *p* Value
  ------------------------------------- ----------------------- -------------------------- ------------------------------- ----------- --------------------------- ------------------------------- -----------
  Age (years)                           62.0 ± 12.8             69.7 ± 10.6                59.5 ± 12.5                     \<0.0001    66.7 ± 12.2                 58.7 ± 12.2                     \<0.0001
  Gender, male/female                   198/191                 36/57                      162/134                         0.0087      93/66                       105/125                         0.0135
  Etiology, HBV/HCV/HBV, and HCV/NBNC   61/234/8/86             10/60/2/21                 51/174/6/65                     0.5130      21/101/5/32                 40/133/3/54                     0.3102
  Presence of LC, yes/no                148/241                 61/32                      87/209                          \<0.0001    65/94                       83/147                          0.3416
  Body mass index (kg/m^2^)             23.2 ± 3.8              22.7 ± 3.3                 23.3 ± 4.0                      0.1554      20.9 ± 2.4                  24.8 ± 3.8                      \<0.0001
  Total bilirubin (mg/dL)               0.96 ± 0.58             0.96 ± 0.62                0.96 ± 0.57                     0.9545      0.86 ± 0.39                 1.02 ± 0.68                     0.0718
  Serum albumin (g/dL)                  4.1 ± 0.5               3.9 ± 0.57                 4.2 ± 0.45                      \<0.0001    4.2 ± 0.48                  4.1 ± 0.52                      0.2688
  Prothrombin time (%)                  86.7 ± 16.6             84.1 ± 17.1                87.5 ± 16.3                     0.0790      87.5 ± 16.9                 86.1 ± 16.3                     0.4112
  Platelet count (×10^4^/mm^3^)         16.8 ± 6.9              15.1 ± 6.5                 17.3 ± 6.9                      0.0081      16.7 ± 6.2                  16.8 ± 7.3                      0.7315
  White blood cell (/mm^3^)             5165 ± 1614             5193 ± 1659                5156 ± 1602                     0.8455      5240 ± 1466                 5113 ± 1710                     0.3114
  Lymphocyte count (/mm^3^)             3112 ± 958              1395 ± 598                 1627 ± 613                      0.0015      1513 ± 542                  1613 ± 661                      0.2045
  Total cholesterol (mg/dL)             181.3 ± 41.3            170.5 ± 47.2               184.7 ± 38.8                    0.0038      182.0 ± 43.9                180.8 ± 39.5                    0.7775
  CONUT score                           1.9 ± 1.9               2.7 ± 2.5                  1.6 ± 1.6                       0.0003      1.9 ± 1.7                   1.9 ± 2.0                       0.8450
  AST (IU/L)                            37.7 ± 27.3             40.3 ± 29.2                36.8 ± 26.6                     0.2886      36.9 ± 26.1                 38.2 ± 28.1                     0.6286
  ALT (IU/L)                            37.3 ± 37.3             35.0 ± 38.4                38.1 ± 37.0                     0.4966      35.4 ± 36.3                 38.7 ± 38.0                     0.3828
  FIB-4 index                           3.3 ± 3.3               4.0 ± 2.8                  3.1 ± 3.4                       0.0142      3.2 ± 2.2                   3.4 ± 3.9                       0.0215
  Serum creatinine (mg/dL)              0.73 ± 0.54             0.76 ± 0.53                0.72 ± 0.55                     0.4769      0.81 ± 0.81                 0.67 ± 0.18                     0.0095
  HbA1c (NGSP)                          5.9 ± 0.88              5.9 ± 0.80                 5.8 ± 0.90                      0.7085      5.9 ± 0.84                  5.8 ± 0.90                      0.7085
  Serum sodium (mmol/L)                 140.1 ± 2.3             139.9 ± 2.5                140.2 ± 2.3                     0.2330      140.3 ± 2.4                 140.0 ± 2.3                     0.3413
  HGS (kg), male                        33.6 ± 8.7              22.0 ± 3.9                 36.3 ± 6.4                      \<0.0001    29.4 ± 6.9                  37.4 ± 7.5                      \<0.0001
  HGS (kg), female                      20.9 ± 5.2              14.8 ± 3.1                 23.3 ± 3.6                      \<0.0001    18.2 ± 4.1                  22.4 ± 5.1                      \<0.0001
  SMI (kg/m^2^), male                   7.5 ± 1.1               7.0 ± 0.97                 7.6 ± 1.09                      0.0039      6.8 ± 0.43                  8.1 ± 1.13                      \<0.0001
  SMI (kg/m^2^), female                 6.0 ± 0.7               5.6 ± 0.74                 6.1 ± 0.68                      \<0.0001    5.2 ± 0.39                  6.4 ± 0.50                      \<0.0001

Data are expressed as average ± standard deviation. HBV; hepatitis B virus, HCV; hepatitis C virus, NBNC; non-B and non-C, LC; liver cirrhosis, CONUT score; controlling nutritional score, AST; aspartate aminotransferase, ALT; alanine aminotransferase, NGSP; National Glycohemoglobin Standardization Program, HGS; hand grip strength, SMM; skeletal muscle mass, SMI; skeletal muscle mass index.

jcm-07-00553-t002_Table 2

###### 

Comparison of the SF-36 scores across 10 items in patients with LC and non-LC.

  ALL Cases   LC Patients (*n* = 148)      Non-LC Patients (*n* = 241)   *p* Value
  ----------- ---------------------------- ----------------------------- -----------
  PF          79.9 ± 20.2 \[76.6, 83.2\]   87.5 ± 15.8 \[85.5, 89.5\]    \<0.0001
  RP          77.0 ± 30.7 \[72.0, 82.0\]   87.2 ± 21.4 \[84.5, 90.0\]    0.0005
  BP          71.6 ± 26.1 \[67.3, 75.9\]   76.3 ± 23.9 \[73.3, 79.3\]    0.0709
  GH          51.6 ± 19.7 \[48.4, 54.8\]   58.4 ± 19.1 \[55.9, 60.9\]    0.0011
  VT          59.3 ± 22.6 \[55.6, 63.0\]   67.6 ± 20.5 \[65.0, 70.2\]    0.0002
  SF          82.9 ± 25.1 \[78.8, 87.0\]   89.4 ± 19.4 \[86.9, 91.9\]    0.0004
  RE          78.6 ± 28.3 \[74.0, 83.3\]   88.1 ± 21.4 \[85.4, 90.8\]    \<0.0001
  MH          73.0 ± 20.6 \[69.6, 76.4\]   74.9 ± 20.7 \[72.2, 77.5\]    0.3845
  PCS         42.3 ± 16.2 \[39.6, 45.1\]   48.7 ± 11.9 \[47.1, 50.2\]    \<0.0001
  MCS         49.9 ± 10.1 \[48.2, 51.6\]   51.8 ± 10.4 \[50.4, 53.1\]    0.0891

Data are expressed as average ± standard deviation and 95% confidence interval. LC; liver cirrhosis, PF; physical functioning, RP; role physical, BP; bodily pain, GH; general health perception, VT; vitality, SF; social functioning, RE; role emotion, MH; mental health, PCS; physical component summary score, MCS; mental component summary score.

jcm-07-00553-t003_Table 3

###### 

Comparison of the SF-36 scores across 10 items.

  ---------------- ------------------------------- ----------------------------------- ---------------
  **ALL Cases**    **Decreased HGS (*n* = 93)**    **Non-Decreased HGS (*n* = 296)**   ***p* Value**
  PF               72.8 ± 22.6 \[68.1, 77.5\]      88.3 ± 14.3 \[86.7, 90.0\]          \<0.0001
  RP               70.6 ± 33.1 \[63.7, 77.4\]      87.3 ± 21.7 \[84.8, 89.8\]          \<0.0001
  BP               68.1 ± 24.0 \[63.2, 73.1\]      76.5 ± 24.8 \[73.7, 79.4\]          0.0043
  GH               54.8 ± 22.7 \[50.1, 59.5\]      56.1 ± 18.5 \[53.9, 58.2\]          0.6190
  VT               57.7 ± 25.1 \[52.5, 62.9\]      66.6 ± 20.0 \[64.3, 68.9\]          0.0011
  SF               79.5 ± 25.4 \[74.2, 84.8\]      89.3 ± 20.2 \[86.9, 91.6\]          \<0.0001
  RE               72.4 ± 30.3 \[66.1, 78.8\]      88.3 ± 21.2 \[85.9, 90.7\]          \<0.0001
  MH               72.3 ± 24.1 \[67.3, 77.3\]      74.7 ± 19.4 \[72.5, 77.0\]          0.7439
  PCS              37.3 ± 16.7 \[33.8, 40.8\]      49.2 ± 11.7 \[47.8, 50.6\]          \<0.0001
  MCS              50.5 ± 11.0 \[48.2, 52.9\]      51.2 ± 10.1 \[50.5, 52.4\]          0.5941
  **ALL Cases**    **Decreased SMM (*n* = 159)**   **Non-Decreased SMM (*n* = 230)**   ***p* Value**
  PF               81.3 ± 18.1 \[78.5, 84.2\]      86.8 ± 17.5 \[84.6, 89.1\]          0.0032
  RP               80.4 ± 27.2 \[76.2, 84.7\]      85.3 ± 24.7 \[82.1, 88.6\]          0.0660
  BP               74.7 ± 25.1 \[70.8, 78.7\]      74.4 ± 24.6 \[71.2, 77.6\]          0.8891
  GH               55.2 ± 20.4 \[52.0, 58.5\]      56.1 ± 19.1 \[53.6, 58.7\]          0.6656
  VT               62.6 ± 23.6 \[58.9, 66.3\]      65.8 ± 20.2 \[63.2, 68.4\]          0.3364
  SF               84.9 ± 24.7 \[80.9, 88.8\]      88.3 ± 19.7 \[85.7, 91.0\]          0.0031
  RE               82.0 ± 26.6 \[77.8, 86.1\]      86.4 ± 23.0 \[83.3, 89.4\]          0.0030
  MH               72.7 ± 22.4 \[69.2, 76.2\]      75.2 ± 19.3 \[72.7, 77.7\]          0.4683
  PCS              45.3 ± 14.2 \[43.0, 47.6\]      47.0 ± 13.9 \[45.1, 48.8\]          0.2610
  MCS              51.3 ± 10.5 \[49.6, 53.0\]      50.8 ± 10.1 \[49.5, 52.2\]          0.6601
  **LC**           **Decreased HGS (*n* = 61)**    **Non-Decreased HGS (*n* = 87)**    ***p* Value**
  PF               71.1 ± 23.1 \[65.2, 77.1\]      86.2 ± 15.0 \[82.9, 89.4\]          0.0002
  RP               68.0 ± 34.0 \[59.3, 76.7\]      83.4 ± 26.5 \[77.7, 89.1\]          0.0006
  BP               65.3 ± 22.8 \[59.5, 71.2\]      76.1 ± 27.5 \[70.2, 82.0\]          0.0002
  GH               51.0 ± 19.9 \[46.0, 56.1\]      52.0 ± 19.7 \[47.7, 56.3\]          0.7691
  VT               53.8 ± 23.7 \[47.7, 59.9\]      63.2 ± 21.1 \[58.7, 67.7\]          0.0132
  SF               76.7 ± 26.8 \[69.8, 83.6\]      87.4 ± 22.9 \[82.4, 92.3\]          0.0112
  RE               67.2 ± 30.9 \[59.3, 75.2\]      86.7 ± 23.3 \[81.7, 91.7\]          \<0.0001
  MH               71.1 ± 22.8 \[65.2, 77.0\]      74.3 ± 18.9 \[70.3, 78.4\]          0.3514
  PCS              34.9 ± 16.5 \[30.7, 39.2\]      47.9 ± 13.7 \[44.8, 50.9\]          \<0.0001
  MCS              49.3 ± 9.7 \[46.8, 51.8\]       50.3 ± 10.5 \[48.0, 52.7\]          0.5382
  **LC**           **Decreased SMM (*n* = 66)**    **Non-Decreased SMM (*n* = 82)**    ***p* Value**
  PF               75.7 ± 20.7 \[70.5, 80.8\]      83.2 ± 19.2 \[79.0, 87.4\]          0.0252
  RP               72.1 ± 31.6 \[64.3, 80.0\]      80.9 ± 29.6 \[74.4, 87.4\]          0.0867
  BP               72.3 ± 26.1 \[65.8, 78.8\]      71.1 ± 26.3 \[65.3, 76.8\]          0.7832
  GH               51.0 ± 20.0 \[46.1, 56.0\]      52.1 ± 19.6 \[47.7, 56.4\]          0.7589
  VT               56.3 ± 24.3 \[50.2, 62.4\]      61.7 ± 21.0 \[57.1, 66.3\]          0.1519
  SF               81.1 ± 28.4 \[74.1, 88.3\]      84.3 ± 22.1 \[79.4, 89.2\]          0.4615
  RE               73.1 ± 31.9 \[65.2, 81.1\]      83.0 ± 24.4 \[77.6, 88.4\]          0.0131
  MH               71.1 ± 23.7 \[65.2, 77.0\]      74.5 ± 17.8 \[70.6, 78.4\]          0.6602
  PCS              41.5 ± 17.2 \[37.2, 45.8\]      43.0 ± 15.5 \[39.5, 46.6\]          0.5729
  MCS              50.4 ± 10.4 \[47.8, 53.1\]      49.4 ± 9.9 \[47.2, 51.7\]           0.5615
  **Non-LC**       **Decreased HGS (*n* = 32)**    **Non-Decreased HGS (*n* = 209)**   ***p* Value**
  PF               76.1 ± 21.6 \[68.1, 84.0\]      89.2 ± 14.0 \[87.3, 91.1\]          \<0.0001
  RP               75.7 ± 30.9 \[64.4, 87.1\]      88.9 ± 19.2 \[86.3, 91.6\]          \<0.0001
  BP               73.5 ± 25.6 \[64.3, 82.7\]      76.7 ± 23.6 \[73.5, 79.9\]          0.4782
  GH               62.0 ± 26.2 \[52.5, 71.5\]      57.8 ± 17.7 \[55.3, 60.3\]          0.0876
  VT               65.0 ± 26.5 \[55.5, 74.6\]      68.0 ± 19.4 \[65.4, 70.7\]          0.4422
  SF               84.9 ± 22.1 \[76.8, 93.0\]      90.1 ± 18.9 \[87.5, 92.7\]          0.1629
  RE               82.5 ± 27.0 \[72.6, 92.4\]      89.0 ± 20.3 \[86.2, 91.7\]          0.0002
  MH               74.6 ± 26.6 \[65.0, 84.2\]      74.9 ± 19.7 \[72.2, 77.6\]          0.4130
  PCS              41.9 ± 16.4 \[35.8, 48.0\]      49.7 ± 10.6 \[48.2, 51.2\]          0.0018
  MCS              53.1 ± 13.1 \[48.2, 58.0\]      51.6 ± 9.9 \[40.2, 52.9\]           0.3525
  **Non-LC**       **Decreased SMM (*n* = 94)**    **Non-Decreased SMM (*n* = 147)**   ***p* Value**
  PF               85.3 ± 14.9 \[82.2, 88.3\]      88.9 ± 16.2 \[86.3, 91.5\]          0.0830
  RP               86.2 ± 21.9 \[81.7, 90.7\]      87.9 ± 21.2 \[84.4, 91.3\]          0.5689
  BP               76.6 ± 24.4 \[71.4, 81.5\]      76.2 ± 23.6 \[72.4, 80.1\]          0.9476
  GH               58.3 ± 20.2 \[54.0, 62.5\]      58.4 ± 18.5 \[55.4, 61.5\]          0.9482
  VT               66.9 ± 22.2 \[62.4, 71.5\]      68.1 ± 19.4 \[64.9, 71.2\]          0.6748
  SF               87.7 ± 21.5 \[83.0, 91.9\]      90.7 ± 17.8 \[87.7, 93.6\]          0.2185
  RE               87.9 ± 20.5 \[83.8, 92.1\]      88.2 ± 22.0 \[84.6, 91.8\]          0.9205
  MH               73.8 ± 21.5 \[69.3, 78.2\]      75.6 ± 20.2 \[72.3, 78.9\]          0.5102
  PCS              48.0 ± 11.1 \[45.7, 50.3\]      49.1 ± 12.4 \[47.1, 51.2\]          0.4689
  MCS              52.0 ± 10.6 \[49.7, 54.2\]      51.6 ± 10.2 \[49.9, 53.3\]          0.8203
  **Male**         **Decreased HGS (*n* = 36)**    **Non-Decreased HGS (*n* = 162)**   ***p* Value**
  PF               72.9 ± 23.7 \[64.9, 80.9\]      88.9 ± 13.9 \[86.7, 91.1\]          \<0.0001
  RP               69.8 ± 34.9 \[58.0, 81.6\]      88.6 ± 20.1 \[85.4, 91.7\]          \<0.0001
  BP               72.2 ± 26.0 \[63.4, 81.0\]      78.9 ± 23.6 \[75.2, 82.5\]          0.1328
  GH               55.1 ± 23.1 \[47.3, 62.9\]      54.7 ± 18.3 \[51.8, 57.6\]          0.9145
  VT               60.2 ± 26.3 \[51.1, 69.2\]      65.8 ± 20.5 \[62.7, 69.0\]          0.1614
  SF               81.2 ± 27.2 \[71.8, 90.5\]      88.9 ± 20.3 \[85.7, 92.1\]          \<0.0001
  RE               71.5 ± 33.2 \[60.1, 82.9\]      88.9 ± 20.8 \[85.6, 92.1\]          \<0.0001
  MH               74.8 ± 24.0 \[66.6, 83.1\]      72.9 ± 20.0 \[69.7, 76.0\]          0.6112
  PCS              37.0 ± 18.7 \[30.6, 43.4\]      50.4 ± 11.6 \[48.5, 52.3\]          \<0.0001
  MCS              52.7 ± 11.5 \[48.8, 56.7\]      50.1 ± 10.3 \[48.4, 51.7\]          0.1817
  **Male**         **Decreased SMM (*n* = 92)**    **Non-Decreased SMM (*n* = 106)**   ***p* Value**
  PF               83.4 ± 16.5 \[80.0. 86.8\]      88.3 ± 17.5 \[84.9, 91.7\]          0.0451
  RP               81.6 ± 26.8 \[76.1, 87.1\]      88.3 ± 21.8 \[84.1, 92.6\]          0.0035
  BP               77.1 ± 24.8 \[72.0, 82.2\]      78.2 ± 23.6 \[73.6, 82.7\]          0.7508
  GH               53.9 ± 20.9 \[49.6, 58.3\]      55.5 ± 17.8 \[52.0, 59.0\]          0.5712
  VT               63.6 ± 24.5 \[58.6, 68.7\]      65.9 ± 18.9 \[62.2, 69.5\]          0.9880
  SF               85.3 ± 25.0 \[80.1, 90.5\]      89.5 ± 18.6 \[85.8, 93.1\]          0.0507
  RE               82.6 ± 27.1 \[77.0, 88.2\]      88.5 ± 21.3 \[84.4, 92.7\]          0.0904
  MH               73.2 ± 22.5 \[68.6, 77.9\]      73.2 ± 19.2 \[69.5, 76.9\]          0.9942
  PCS              46.3 ± 14.6 \[43.3, 49.4\]      49.4 ± 13.7 \[46.6, 52.1\]          0.1419
  MCS              51.1 ± 11.2 \[48.7, 53.4\]      50.1 ± 10.1 \[48.1, 52.1\]          0.5428
  **Female**       **Decreased HGS (*n* = 57)**    **Non-Decreased HGS (*n* = 134)**   ***p* Value**
  PF               72.7 ± 22.1 \[66.8, 78.7\]      87.6 ± 14.9 \[85.0, 90.1\]          \<0.0001
  RP               71.1 ± 32.2 \[62.5, 79.7\]      85.8 ± 23.4 \[81.8, 89.8\]          \<0.0001
  BP               65.6 ± 22.5 \[59.6, 71.6\]      73.6 ± 25.9 \[69.2, 78.1\]          0.0432
  GH               54.6 ± 22.7 \[48.6, 60.6\]      57.8 ± 18.6 \[54.5, 61.0\]          0.3266
  VT               56.2 ± 24.5 \[49.7, 62.7\]      67.5 ± 19.4 \[64.2, 70.9\]          0.0006
  SF               78.4 ± 24.5 \[71.9, 85.0\]      89.7 ± 20.1 \[86.2, 93.3\]          0.0012
  RE               73.0 ± 8.7 \[65.3, 80.7\]       87.6 ± 21.7 \[83.9, 91.3\]          \<0.0001
  MH               70.8 ± 24.3 \[64.3, 77.2\]      77.1 ± 18.5 \[73.9, 80.3\]          0.1394
  PCS              37.4 ± 15.5 \[33.2, 41.6\]      47.7 ± 11.6 \[45.7, 49.8\]          \<0.0001
  MCS              49.2 ± 10.5 \[46.3, 52.0\]      52.6 ± 9.6 \[50.9, 54.3\]           0.0326
  **Female**       **Decreased SMM (*n* = 66)**    **Non-Decreased SMM (*n* = 125)**   ***p* Value**
  PF               78.5 ± 19.9 \[73.6, 83.5\]      85.6 ± 17.5 \[82.5, 88.7\]          0.0124
  RP               78.8 ± 27.8 \[71.9, 85.7\]      82.8 ± 26.7 \[78.1, 87.6\]          0.3273
  BP               71.3 ± 25.3 \[65.0, 77.6\]      71.1 ± 25.2 \[66.7, 75.6\]          0.9672
  GH               57.1 ± 19.7 \[52.2, 62.0\]      56.6 ± 20.2 \[53.0, 60.3\]          0.8853
  VT               61.1 ± 22.3 \[55.6, 66.6\]      65.7 ± 21.2 \[61.9, 69.5\]          0.1652
  SF               84.2 ± 24.5 \[78.2, 90.3\]      87.4 ± 20.6 \[83.7, 91.2\]          0.3527
  RE               81.0 ± 26.2 \[74.6, 87.5\]      84.5 ± 24.1 \[80.3, 88.8\]          0.3546
  MH               71.9 ± 22.4 \[66.4, 77.5\]      76.9 ± 19.4 \[73.4, 80.3\]          0.1161
  PCS              43.9 ± 13.7 \[40.4, 47.3\]      45.0 ± 13.8 \[42.5, 47.5\]          0.5979
  MCS              51.7 ± 9.7 \[49.3, 54.1\]       51.5 ± 10.2 \[49.6, 53.3\]          0.8719
  **≥65 years**    **Decreased HGS (*n* = 74)**    **Non-Decreased HGS (*n* = 121)**   ***p* Value**
  PF               72.8 ± 23.5 \[67.3, 78.3\]      84.9 ± 14.0 \[82.3, 87.4\]          0.0001
  RP               68.8 ± 34.6 \[60.8, 76.9\]      86.3 ± 20.6 \[82.6, 90.1\]          \<0.0001
  BP               68.8 ± 24.3 \[63.2, 74.4\]      78.0 ± 24.1 \[73.6, 82.4\]          0.0111
  GH               57.6 ± 23.3 \[52.2, 63.0\]      56.8 ± 18.9 \[53.3, 60.3\]          0.7950
  VT               57.9 ± 25.7 \[52.0. 63.9\]      68.9 ± 19.8 \[65.3, 72.5\]          0.0021
  SF               78.3 ± 25.1 \[72.5, 84.1\]      91.1 ± 18.3 \[87.7, 94.4\]          \<0.0001
  RE               71.5 ± 30.6 \[64.4, 78.7\]      88.0 ± 20.5 \[84.2, 91.7\]          \<0.0001
  MH               73.0 ± 25.1 \[67.2, 78.8\]      77.4 ± 17.9 \[74.1, 80.6\]          0.5509
  PCS              36.5 ± 17.6 \[32.4, 40.6\]      47.2 ± 10.1 \[45.3, 49.1\]          \<0.0001
  MCS              51.5 ± 11.2 \[48.9, 54.1\]      53.5 ± 9.2 \[51.8, 55.2\]           0.1822
  **≥65 years**    **Decreased SMM (*n* = 110)**   **Non-Decreased SMM (*n* = 85)**    ***p* Value**
  PF               78.5 ± 18.6 \[75.0, 82.1\]      82.6 ± 19.4 \[78.4, 86.8\]          0.1435
  RP               78.3 ± 28.6 \[72.8, 83.7\]      81.6 ± 27.4 \[75.6, 87.5\]          0.4226
  BP               73.9 ± 26.2 \[68.9, 78.9\]      75.2 ± 22.4 \[70.3, 80.0\]          0.7338
  GH               56.6 ± 21.9 \[52.4, 60.8\]      57.8 ± 19.0 \[53.6, 62.0\]          0.6926
  VT               62.8 ± 24.4 \[58.2, 67.4\]      67.2 ± 20.6 \[62.8, 71.7\]          0.1809
  SF               85.5 ± 23.8 \[80.9, 90.0\]      86.9 ± 19.5 \[82.6, 91.2\]          0.6548
  RE               80.1 ± 27.3 \[74.9, 85.2\]      83.9 ± 24.2 \[78.6, 89.3\]          0.3090
  MH               74.0 ± 22.3 \[69.8, 78.2\]      77.9 ± 19.1 \[73.8, 82.1\]          0.1972
  PCS              43.3 ± 14.1 \[40.6, 45.9\]      42.7 ± 15.2 \[39.3, 46.1\]          0.7951
  MCS              52.8 ± 10.1 \[50.9, 54.7\]      52.6 ± 10.1 \[50.4, 54.9\]          0.9288
  **\<65 years**   **Decreased HGS (*n* = 19)**    **Non-Decreased HGS (*n* = 175)**   ***p* Value**
  PF               72.8 ± 19.6 \[63.3, 82.2\]      90.7 ± 14.1 \[88.6, 92.8\]          \<0.0001
  RP               77.3 ± 25.9 \[64.8, 89.8\]      88.0 ± 22.4 \[84.6, 91.3\]          0.0530
  BP               65.5 ± 23.1 \[54.4, 76.7\]      75.5 ± 25.2 \[71.8, 79.3\]          0.0990
  GH               44.0 ± 16.9 \[35.8, 52.1\]      55.6 ± 18.3 \[52.8, 58.4\]          0.0088
  VT               56.8 ± 23.2 \[45.3, 68.3\]      65.0 ± 20.0 \[62.0, 68.0\]          0.1042
  SF               84.6 ± 27.1 \[70.7, 98.6\]      88.1 ± 21.3 \[84.9, 91.3\]          0.5338
  RE               76.2 ± 29.8 \[61.4, 91.0\]      88.5 ± 21.7 \[85.3, 91.8\]          0.0281
  MH               69.4 ± 20.2 \[59.3, 79.4\]      73.0 ± 20.3 \[70.0, 76.0\]          0.4708
  PCS              40.5 ± 11.8 \[34.4, 46.6\]      50.5 ± 12.5 \[48.6, 52.4\]          0.0018
  MCS              46.5 ± 9.4 \[41.7, 51.3\]       49.6 ± 10.3 \[48.1, 51.2\]          0.2286
  **\<65 years**   **Decreased SMM (*n* = 49)**    **Non-Decreased SMM (*n* = 145)**   ***p* Value**
  PF               87.7 ± 15.1 \[83.4, 92.1\]      89.3 ± 15.8 \[86.7, 91.9\]          0.5386
  RP               85.2 ± 23.3 \[78.6, 91.9\]      87.5 ± 22.8 \[83.8, 91.3\]          0.5501
  BP               76.5 ± 22.8 \[69.9, 83.0\]      73.9 ± 25.9 \[69.7, 78.2\]          0.5389
  GH               52.0 ± 16.1 \[47.3, 56.8\]      55.2 ± 19.1 \[52.0, 58.4\]          0.3182
  VT               62.2 ± 21.9 \[55.8, 68.5\]      65.0 ± 19.9 \[61.7, 68.2\]          0.4133
  SF               83.4 ± 26.9 \[75.5, 91.4\]      89.2 ± 19.8 \[85.9, 92.5\]          0.0286
  RE               86.3 ± 24.8 \[79.1, 93.5\]      87.7 ± 22.2 \[84.1, 91.4\]          0.7097
  MH               69.7 ± 22.5 \[63.2, 76.3\]      73.6 ± 19.4 \[70.4, 76.8\]          0.2510
  PCS              50.2 ± 13.6 \[46.1, 54.3\]      49.4 ± 12.5 \[47.3, 51.5\]          0.7120
  MCS              47.9 ± 10.9 \[44.6, 51.1\]      49.8 ± 10.0 \[48.2, 51.5\]          0.2593
  ---------------- ------------------------------- ----------------------------------- ---------------

Data are expressed as average ± standard deviation and 95% confidence interval. HGS; hand grip strength, SMM; skeletal muscle mass, LC; liver cirrhosis, PF; physical functioning, RP; role physical, BP; bodily pain, GH; general health perception, VT; vitality, SF; social functioning, RE; role emotion, MH; mental health, PCS; physical component summary score, MCS; mental component summary score.
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###### 

Relationship between baseline data and the SF-36 scores in each item in male and female patients.

  ------------ --------------- ---------- --------------- ---------- --------------- --------- --------------- ---------- --------------- --------
  **Male**     **PF**          **RP**     **BP**          **GH**     **VT**                                                               
  ***r***      ***p* Value**   ***r***    ***p* Value**   ***r***    ***p* Value**   ***r***   ***p* Value**   ***r***    ***p* Value**   
  Age          −0.21           0.0036     −0.12           0.0939     −0.12           0.0869    0.11            0.1298     0.069           0.3346
  BMI          −0.057          0.4246     −0.051          0.4740     −0.047          0.5091    0.039           0.5925     −0.044          0.5394
  HGS          0.32            \<0.0001   0.25            0.0007     0.048           0.5242    −0.016          0.8924     0.0058          0.9383
  SMI          −0.0066         0.9268     −0.0028         0.9685     −0.081          0.2577    −0.00035        0.9961     −0.062          0.3920
  Albumin      0.42            \<0.0001   0.38            \<0.0001   0.21            0.0025    0.18            0.0143     0.25            0.0005
  Bilirubin    0.011           0.8784     −0.021          0.7731     −0.041          0.5686    −0.061          0.4026     −0.0278         0.7018
  PT           0.26            0.0002     0.16            0.0245     0.063           0.3773    0.17            0.0209     0.19            0.0086
  Platelet     0.11            0.1250     0.042           0.5583     −0.031          0.6653    0.11            0.1449     0.020           0.7802
  CONUT        −0.4            \<0.0001   −0.30           \<0.0001   −0.12           0.0924    −0.17           0.0164     −0.17           0.0181
  AST          −0.01           0.1626     −0.27           0.0013     −0.15           0.0412    −0.21           0.0030     −0.16           0.0220
  ALT          −0.027          0.7035     −0.18           0.0104     −0.11           0.1393    −0.17           0.0189     −0.13           0.0707
  **Male**     **SF**          **RE**     **MH**          **PCS**    **MCS**                                                              
  ***r***      ***p* Value**   ***r***    ***p* Value**   ***r***    ***p* Value**   ***r***   ***p* Value**   ***r***    ***p* Value**   
  Age          −0.019          0.7916     −0.064          0.3732     0.14            0.0509    −0.24           0.0011     0.22            0.0030
  BMI          −0.046          0.5294     0.055           0.4441     0.031           0.6637    −0.083          0.260      0.0099          0.8930
  HGS          0.10            0.1827     0.16            0.0324     −0.10           0.1772    0.29            0.0001     −0.16           0.0353
  SMI          −0.043          0.5601     0.056           0.4391     0.046           0.5193    −0.050          0.4976     −0.02           0.7834
  Albumin      0.27            0.0002     0.33            \<0.0001   0.086           0.2273    0.46            \<0.0001   0.046           0.5348
  Bilirubin    −0.064          0.3845     −0.0071         0.9215     0.067           0.3569    −0.02           0.7925     −0.035          0.6371
  PT           0.16            0.0286     0.10            0.1503     0.020           0.7849    0.19            0.0088     0.069           0.3468
  Platelet     0.10            0.1614     −0.040          0.5762     −0.1243         0.0818    0.051           0.4905     −0.023          0.7590
  CONUT        −0.19           0.0091     −0.21           0.0031     0.026           0.7197    0.36            \<0.0001   0.011           0.8773
  AST          −0.070          0.3345     −0.19           0.0071     −0.13           0.0675    −0.16           0.0286     −0.12           0.1021
  ALT          −0.025          0.7311     −0.20           0.0050     −0.15           0.0331    0.10            0.1650     −0.11           0.1172
  **Female**   **PF**          **RP**     **BP**          **GH**     **VT**                                                               
  ***r***      ***p* Value**   ***r***    ***p* Value**   ***r***    ***p* Value**   ***r***   ***p* Value**   ***r***    ***p* Value**   
  Age          −0.25           0.0004     −0.15           0.0384     0.051           0.4835    0.077           0.2987     −0.035          0.6346
  BMI          −0.037          0.6128     −0.0065         0.9292     −0.025          0.7329    −0.0248         0.7383     0.0059          0.9357
  HGS          0.35            \<0.0001   0.18            0.0195     0.098           0.1953    0.054           0.4815     0.23            0.0022
  SMI          0.20            0.0053     0.10            0.1677     −0.048          0.5136    −0.0055         0.9409     0.096           0.1877
  Albumin      0.24            0.0011     0.27            0.0002     0.15            0.0407    0.16            0.0351     0.20            0.0058
  Bilirubin    −0.078          0.2909     −0.18           0.0133     −0.13           0.0711    −0.092          0.2216     −0.11           0.1427
  PT           0.021           0.7759     0.12            0.0978     0.066           0.3663    0.088           0.2349     0.14            0.0552
  Platelet     0.11            0.1247     0.13            0.080      0.069           0.3444    0.040           0.5908     0.083           0.2585
  CONUT        −0.2            0.0051     −0.27           0.0002     −0.16           0.0246    −0.19           0.0088     −0.15           0.0423
  AST          −0.11           0.1441     −0.12           0.1023     −0.10           0.1521    −0.094          0.2403     −0.17           0.0181
  ALT          −0.03           0.6782     −0.039          0.5944     −0.14           0.0507    −0.087          0.2403     −0.13           0.0662
  **Female**   **SF**          **RE**     **MH**          **PCS**    **MCS**                                                              
  ***r***      ***p* Value**   ***r***    ***p* Value**   ***r***    ***p* Value**   ***r***   ***p* Value**   ***r***    ***p* Value**   
  Age          0.017           0.8212     −0.11           0.1373     −0.021          0.7774    −0.20           0.0066     0.097           0.1948
  BMI          −0.012          0.8759     −0.0045         0.9511     −0.0075         0.9186    −0.062          0.4035     −0.044          0.5541
  HGS          0.18            0.0179     0.19            0.0112     0.17            0.0222    0.28            0.0003     0.15            0.0446
  SMI          0.025           0.7319     0.11            0.1375     0.057           0.4395    0.087           0.2433     −0.060          0.4255
  Albumin      0.20            0.0072     0.19            0.0098     0.12            0.0878    0.30            \<0.0001   0.15            0.0481
  Bilirubin    −0.18           0.0148     −0.16           0.0304     −0.04           0.5927    −0.21           0.0043     −0.074          0.3295
  PT           0.14            0.0503     0.13            0.0766     0.12            0.1036    0.12            0.1030     0.19            0.0119
  Platelet     0.098           0.1837     0.12            0.1067     0.12            0.1103    0.16            0.0311     0.093           0.2115
  CONUT        −0.17           0.0253     −0.17           0.0206     0.081           0.2708    −0.31           \<0.0001   −0.11           0.1407
  AST          −0.16           0.0336     −0.13           0.0719     −0.16           0.0245    −0.11           0.1386     −0.17           0.0206
  ALT          −0.084          0.2597     −0.051          0.4811     −0.98           0.1817    −0.025          0.7397     −0.15           0.0462
  ------------ --------------- ---------- --------------- ---------- --------------- --------- --------------- ---------- --------------- --------

PF; physical functioning, RP; role physical, BP; bodily pain, GH; general health perception, VT; vitality, SF; social functioning, RE; role emotion, MH; mental health, PCS; physical component summary score, MCS; mental component summary score, BMI; body mass index, HGS; hand grip strength, SMI; skeletal muscle mass index, PT; prothrombin time, CONUT; controlling nutritional score, AST; aspartate aminotransferase, ALT; alanine aminotransferase.
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###### 

Multivariate analyses of factors linked to the SF-36 scores in male and female patients.

  --------------- ----------------------------------------- --------------- -------------------- ---------------
  **Male**        **Parameter (Significant Factor Only)**   **Estimates**   **Standard Error**   ***p* Value**
  PF              HGS                                       0.494           0.104                0.0031
  Serum albumin   9.008                                     3.152           0.0048               
  CONUT score     −1.656                                    0.796           0.0389               
  RP              HGS                                       0.579           0.244                0.0185
  Serum albumin   17.593                                    4.899           0.0004               
  BP              NA                                        NA              NA                   NA
  GH              NA                                        NA              NA                   NA
  VT              Serum albumin                             8.944           4.158                0.0327
  SF              Serum albumin                             10.456          3.929                0.0085
  RE              Serum albumin                             18.765          4.891                0.0002
  ALT             −0.245                                    0.0845          0.0042               
  MH              NA                                        NA              NA                   NA
  PCS             HGS                                       0.288           0.141                0.0421
  Serum albumin   11.016                                    2.692           \<0.0001             
  MCS             NA                                        NA              NA                   NA
  **Female**      **Parameter (significant factor only)**   **Estimates**   **Standard error**   ***p* Value**
  PF              HGS                                       0.958           0.322                0.0034
  RP              NA                                        NA              NA                   NA
  BP              NA                                        NA              NA                   NA
  GH              NA                                        NA              NA                   NA
  VT              HGS                                       0.851           0.346                0.0150
  SF              NA                                        NA              NA                   NA
  RE              HGS                                       0.729           0.36                 0.0422
  MH              AST                                       −0.124          0.0609               0.0440
  PCS             HGS                                       0.521           0.22                 0.0191
  MCS             NA                                        NA              NA                   NA
  --------------- ----------------------------------------- --------------- -------------------- ---------------

PF; physical functioning, RP; role physical, BP; bodily pain, GH; general health perception, VT; vitality, SF; social functioning, RE; role emotion, MH; mental health, PCS; physical component summary score, MCS; mental component summary score, HGS; hand grip strength, CONUT score; controlling nutritional score, NA; not applicable, ALT; alanine aminotransferase, AST; aspartate aminotransferase.
